Topical haemostatics in renal trauma - An evaluation of four different substances in an experimental setting

Journal of Trauma - Injury, Infection and Critical Care

Volumn 66, Issue 3, 2009, Pages 602-611

  Björses, Katarina ^a,b   Holst, Jan ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bovine thrombin; Experimental bleeding model; Gelatin; Local hemostatic agent; rFVIIA

Indexed keywords

FLOSEAL; GELATIN; GELATIN SPONGE; HEMOSTATIC AGENT; HEPARIN; HEPARIN LEO; POLYSACCHARIDE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SPONGOSTAN; THROMBIN; TRAUMADEX; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 7A; FLOSEAL MATRIX; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT; FEMALE; HEMINEPHRECTOMY; HEMOSTASIS; HEPARINIZATION; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BLEEDING; BLEEDING TIME; COMPARATIVE STUDY; DRUG COMBINATION; INJURY; KIDNEY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; BLEEDING TIME; DRUG THERAPY, COMBINATION; FACTOR VIIA; GELATIN; GELATIN SPONGE, ABSORBABLE; HEMORRHAGE; HEMOSTATICS; KIDNEY; POLYSACCHARIDES; RATS; RECOMBINANT PROTEINS; THROMBIN;

EID: 68149157764     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3181823533     Document Type: Article

References (35)

1. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: a reassessment. J Trauma. 1995;38:185-193.
2. Johnson JW, Gracias VH, Schwab CW, et al. Evolution in damage control for exsanguinating penetrating abdominal injury. J Trauma. 2001;51:261-269; discussion 9-71.
3. Shapiro MB, Jenkins DH, Schwab CW, Rotondo MF. Damage control: collective review. J Trauma. 2000;49:969 -978.
4. Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma. 2007;62:307-310.
5. L'Esperance JO, Sung JC, Marguet CG, et al. Controlled survival study of the effects of Tisseel or a combination of FloSeal and Tisseel on major vascular injury and major collecting-system injury during partial nephrectomy in a porcine model. J Endourol Endourol Soc. 2005;19:1114 -1121.
6. Raccuia JS, Simonian G, Dardik M, et al. Comparative efficacy of topical hemostatic agents in a rat kidney model. Am J Surg. 1992; 163:234 -238.
7. Hick EJ, Morey AF, Harris RA, Morris MS. Gelatin matrix treatment of complex renal injuries in a porcine model. J Urol. 2005;173:1801-1804.
8. Griffith BC, Morey AF, Rozanski TA, et al. Central renal stab wounds: treatment with augmented fibrin sealant in a porcine model. J Urol. 2004;171:445- 447.
9. Krishnan LK, Mohanty M, Umashankar PR, Lal AV. Comparative evaluation of absorbable hemostats: advantages of fibrin-based sheets. Biomaterials. 2004;25:5557-5563.
10. Pursifull NF, Morris MS, Harris RA, Morey AF. Damage control management of experimental grade 5 renal injuries: further evaluation of FloSeal gelatin matrix. J Trauma. 2006;60:346 -350.
11. Jackson MR, Taher MM, Burge JR, Krishnamurti C, Reid TJ, Alving BM. Hemostatic efficacy of a fibrin sealant dressing in an animal model of kidney injury. J Trauma. 1998;45:662- 665.
12. Petratos PB, Ito K, Felsen D, Poppas D. Cross-linked matrix tissue sealant protects against mortality and hemorrhage in an acute renal injury model in heparinized rats. J Urol. 2002;167:2222-2224.
13. Murat FJ, Ereth MH, Dong Y, Piedra MP, Gettman MT. Evaluation of microporous polysaccharide hemospheres as a novel hemostatic agent in open partial nephrectomy: favorable experimental results in the porcine model. J Urol. 2004;172:1119 -1122.
14. Pusateri AE, Modrow HE, Harris RA, et al. Advanced hemostatic dressing development program: animal model selection criteria and results of a study of nine hemostatic dressings in a model of severe large venous hemorrhage and hepatic injury in Swine. J Trauma. 2003;55:518 -526.
15. Alam HB, Uy GB, Miller D, et al. Comparative analysis of hemostatic agents in a swine model of lethal groin injury. J Trauma. 2003;54:1077-1082.
16. Kheirabadi BS, Field-Ridley A, Pearson R, MacPhee M, Drohan W, Tuthill D. Comparative study of the efficacy of the common topical hemostatic agents with fibrin sealant in a rabbit aortic anastomosis model. J Surg Res. 2002;106:99 -107.
17. Unlu Y, Vural U, Kocak H, Ceviz M, Becit N, Akbulut O. Comparison of the topical haemostatic agents for the prevention of suture hole bleeding. An experimental study. Eur J Vasc Endovasc Surg. 2002;23:441- 444.
18. Tuthill DD, Bayer V, Gallagher AM, Drohan WN, MacPhee MJ. Assessment of topical hemostats in a renal hemorrhage model in heparinized rats. J Surg Res. 2001;95:126 -132.
19. Bjorses K, Holst J. Various local hemostatic agents with different modes of action; an in vivo comparative randomized vascular surgical experimental study. Eur J Vasc Endovasc Surg. 2007; 33:363-370.
20. Humphreys MR, Castle EP, Andrews PE, Gettman MT, Ereth MH. Microporous polysaccharide hemospheres for management of laparoscopic trocar injury to the spleen. Am J Surg. 2008;195:99-103.
21. Wagner WR, Pachence JM, Ristich J, Johnson PC. Comparative in vitro analysis of topical hemostatic agents. J Surg Res. 1996;66:100-108.
22. Wolberg AS, Meng ZH, Monroe DM III, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma. 2004;56:1221-1228.
23. Michelson AD, Barnard MR, Khuri SF, Rohrer MJ, MacGregor H, Valeri CR. The effects of aspirin and hypothermia on platelet function in vivo. Br J Haematol. 1999;104:64-68.
24. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev. 2007;21:131-142.
25. Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and hemostasis. Transfus Apher Sci. 2008;38:15-23.
26. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem. 2007;40:431- 442.
27. Dahlback B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Int Med. 2005;257:209 -223.
28. Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vascul Biol. 2008;28:233-242.
29. Lupu C, Lupu F, Dennehy U, Kakkar VV, Scully MF. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arterioscler Thromb Vascul Biol. 1995;15:2055-2062.
30. He S, Ekman GJ, Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost. 2005;3:272-279.
31. Hedner U. Recombinant factor VIIa: its background, development and clinical use. Curr Opin Hematol. 2007;14:225-229.
32. Rapaport SI, Zivelin A, Minow RA, Hunter CS, Donnelly K. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 1992;97:84 -91.
33. Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002; 42:18 -26.
34. Stricker RB, Lane PK, Leffert JD, Rodgers GM, Shuman MA, Corash L. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood. 1988;72:1375-1380.
35. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007;205:256 -265.